Martin Reck

981 posts

Martin Reck banner
Martin Reck

Martin Reck

@MartinReck2

Working on medicine

เข้าร่วม Haziran 2019
228 กำลังติดตาม1.4K ผู้ติดตาม
Martin Reck รีทวีตแล้ว
Xiuning Le MD PhD
Xiuning Le MD PhD@LeXiuning·
😊 🩷 Nice to see friends and colleagues in the #lungcancer community from different continents at #ELCC26. @caliraf @Alfdoc2 @HHorinouchi @MartinReck2 @Tony_Calles @DoctorJSpicer @fred_hirsch @bensolomon1 @NReguart @BalazsHalmosMD @BrendonStilesMD @mollylisc @karenkellymd @ThomasW35874311 @NadalErnest @DrSanjayPopat 😊 🩷 Safe travels ✈️ 💐💐💐Grateful for the wonderful organization between @IASLC and @esmo for an impactful and fun #ELCC26.
Xiuning Le MD PhD tweet media
English
1
7
46
2.3K
Martin Reck รีทวีตแล้ว
Giannis Mountzios
Giannis Mountzios@g_mountzios·
Back home from an amazing #ELCC26, I keep reflecting on the true value of scientific meetings: The best science and education comes only among people who are unite by friendship, mutual respect and a common vision: to improve the care of our patients with lung cancer See you all in #ELCC27! @myESMO @IASLC
Giannis Mountzios tweet mediaGiannis Mountzios tweet mediaGiannis Mountzios tweet mediaGiannis Mountzios tweet media
English
1
12
47
2.3K
Martin Reck รีทวีตแล้ว
Hidehito HORINOUCHI
Hidehito HORINOUCHI@HHorinouchi·
🆙 #ELCC26 @myESMO @IASLC 🇩🇰 🔥Mini Oral session 2 ☑️KEYNOTE-671: 5 years F/U in non-pCR subgroup 🎯EFS HR 0.69, 5-y rate 42.9% vs. 25.2%, OS immature 🎙️ @MartinReck2 🎙️Chair: Dr. Kersti Oselin @MARIANOPROVENCI 📍NCT03425643 @OncoAlert @Larvol #LCSM
Hidehito HORINOUCHI tweet mediaHidehito HORINOUCHI tweet mediaHidehito HORINOUCHI tweet mediaHidehito HORINOUCHI tweet media
Hidehito HORINOUCHI@HHorinouchi

🆙 #ELCC26 @myESMO 🇩🇰 🔥Mini Oral session 2 ☑️KEYNOTE-671: 5 years F/U in non-pCR subgroup 🎯EFS HR 0.69, 5-y rate 42.9% vs. 25.2%, OS immature 🎙️ @MartinReck2 🎙️Chair: Dr. Kersti Oselin @MARIANOPROVENCI 📍NCT03425643 @OncoAlert @Larvol #LCSM

Indonesia
0
5
10
1.5K
Martin Reck รีทวีตแล้ว
Giannis Mountzios
Giannis Mountzios@g_mountzios·
#ELCC26 @MartinReck2 on KN671 exploratory analysis of patients without pCR 5-year EFS 43% vs 25% , HR =0,69, 95%CI 0.57-0.83)
Giannis Mountzios tweet mediaGiannis Mountzios tweet media
English
1
14
32
2.1K
Martin Reck รีทวีตแล้ว
Thoracic Oncology Frontier
Thoracic Oncology Frontier@IONCOLOGYLung·
#ELCC26 Day3 Mini Oral @MartinReck2 presented "Exploratory Analysis of Participants Without Pathological Complete Response (pCR) in the KEYNOTE-671 Study of Perioperative Pembrolizumab (Pembro) in Early-Stage #NSCLC After 5 Years of Follow-Up" @IASLC @myESMO
Thoracic Oncology Frontier tweet mediaThoracic Oncology Frontier tweet mediaThoracic Oncology Frontier tweet mediaThoracic Oncology Frontier tweet media
English
0
1
2
328
Martin Reck รีทวีตแล้ว
d.planchard
d.planchard@dplanchard·
Always a privilege to listen to one of the true pioneers of immunotherapy in thoracic oncology @MartinReck2 . Inspiring as ever ! @myESMO
d.planchard tweet mediad.planchard tweet mediad.planchard tweet mediad.planchard tweet media
English
0
6
26
1.5K
Martin Reck รีทวีตแล้ว
Balazs Halmos
Balazs Halmos@BalazsHalmosMD·
I am starting to notice that after 20+ yrs of oncology some of my skills are starting to be as good as that of a top Ortho surgeon!
Balazs Halmos tweet media
English
1
3
23
2.1K
Martin Reck รีทวีตแล้ว
International Lung Cancer Summit
A new therapeutic opportunity is emerging in MTAP-deleted NSCLC using PRMT5 inhibitors. During our Year in Review roundtable with @peters_solange, @MartinReck2 and @charlesrudin, we learned how this new class of drugs may target 10% to 30% of all NSCLC cases. These compounds are also being developed in other solid tumors and are now moving into frontline strategies with chemo and potentially IO. Watch the full roundtable here ⬇️ lungsummit.org/all-sessions/
English
0
12
32
2K
Martin Reck
Martin Reck@MartinReck2·
Just out! Delighted to share some work on (IO) refractory Lung Cancer. Thank you for a fantastic cooped! Feasibility and safety of nintedanib in combination with nivolumab in ... sciencedirect.com/science/articl… #LCSM
English
0
0
4
335
Martin Reck รีทวีตแล้ว
International Lung Cancer Summit
How do we best handle progression in EGFR mutant NSCLC? @MartinReck2 linked the frontline selection model from @ZosiaPiotrowska to resistance strategies defined by @RamalingamMD. With 4th generation targets remaining rare the focus shifts to MET alterations. Options for treatment include the use of amivantamab, which was done in the MARIPOSA-2 trial, or the combination of osimertinib and savolitinib as shown here with the SACHI trial. Watch the full talk with @peters_solange and @charlesrudin ➡️ lungsummit.org/targeted-thera…
English
1
9
76
2.4K
Martin Reck รีทวีตแล้ว
Stephen V Liu, MD
Stephen V Liu, MD@StephenVLiu·
Toughest debate at #ITCD2026: Italian vs German sensibilities! 🍷🍺
Stephen V Liu, MD tweet media
English
0
2
24
1.4K
Martin Reck รีทวีตแล้ว
Cecilia Pompili MD PhD FACS
Cecilia Pompili MD PhD FACS@pompili_cecilia·
Fantastic discussion at #ITD2026 with Dr @NarjustFlorez on neoadjuvant approaches with targeted therapy. Really inspiring discussion around surgical considerations and different perspectives on NeoAdaura data. #ITCD2026
Cecilia Pompili MD PhD FACS tweet mediaCecilia Pompili MD PhD FACS tweet mediaCecilia Pompili MD PhD FACS tweet media
English
0
4
10
842
Martin Reck รีทวีตแล้ว
Stephen V Liu, MD
Stephen V Liu, MD@StephenVLiu·
Dr. @delvysra at #ITCD2026 explains why targeting PD-1 and VEGF holds such promise with bispecific antibodies like ivonescimab and pumitamig now in the clinic. Intriguing efficacy signals and safety seems better than separate antibodies.
Stephen V Liu, MD tweet mediaStephen V Liu, MD tweet mediaStephen V Liu, MD tweet mediaStephen V Liu, MD tweet media
English
2
10
36
2.9K
Martin Reck รีทวีตแล้ว
Manuel Dómine, MD, PhD
Manuel Dómine, MD, PhD@ManuelDomine·
IV International Thoracic Cancer Debates #ITCD26. Gran Canaria, Spain. Very proud to participate in this session on #SCLC with excellent experts, Great advances in SCLC. Thanks @delvysra #LCSM @OncoAlert @myESMO @Hospital_FJD @quironsalud @UAM_Madrid @AEACaP #IIS-FJD #Lungcancer
Manuel Dómine, MD, PhD tweet mediaManuel Dómine, MD, PhD tweet media
Giannis Mountzios@g_mountzios

A superb session on the 2nd day of #ITCD26 focusing on #SCLC chaired by Rolf Stahel and @ElinardouHelena . Great to contribute alongside great colleagues and friends @StephenVLiu and @DrJNaidoo , followed be brainstorming discussions. Big 🙏to great hosts @delvysra @rosariogarc #LCSM #some @OncBrothers @OncoAlert @HeSMO_X @Women4Oncology

English
0
4
13
2.6K
Martin Reck รีทวีตแล้ว
Narjust Florez, MD, FASCO
Narjust Florez, MD, FASCO@NarjustFlorezMD·
✨What comes first in EGFR-m NSCLC the neo or the adjuvant? Or are we entering the era of both? It was a pleasure presenting this evolving perioperative puzzle at #ITCD2026 in beautiful Gran Canaria 🇮🇨 Exciting times ahead for targeted therapy in early-stage lung cancer!
Narjust Florez, MD, FASCO tweet mediaNarjust Florez, MD, FASCO tweet mediaNarjust Florez, MD, FASCO tweet mediaNarjust Florez, MD, FASCO tweet media
English
1
7
24
1.6K